Cyclo Therapeutics Inc (CYTH) Gross Profit Margin starting from the third quarter 2024 to third quarter 2023, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Cyclo Therapeutics Inc   (NASDAQ: CYTH)


Cyclo Therapeutics Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYTH Gross Profit Margin (Sep 30 2024)
Q3 		(Jun 30 2024)
Q2 		(Mar 31 2024)
Q1 		(Dec 31 2023)
Q4 		(Sep 30 2023)
Q3
Y / Y Revenue Change -52.82 %
Seq. Revenue Change 89.9 %
Revenue In Millions $0.23
Gross Profit Margin 92.81 %
Gross Profit Margin Total Ranking # 932
Gross Profit In Millions $0.22
Y / Y Gross Profit Change -
Seq. Gross Profit Change 97.75 %


Commenting Third Quarter 2024 Gross Profit Margin
Cyclo Therapeutics Inc Gross Profit grew by 97.75 % in Q3 sequentially to 0 millions, while Revenue increased by 89.9 %, this led to improvement in the company's Gross Profit Margin to 92.81 %, above the Cyclo Therapeutics Inc average Gross Profit Margin.


Observing third quarter 2024 results within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 932.
Learn about Gross Margin
CYTH's Gross Profit Margin third quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 18
Healthcare Sector # 154
Overall # 918

Gross Profit Margin Statistics
High Average Low
94.19 % 84.88 % 70.87 %
(Sep 30 2018)   (Dec 31 2015)


CYTH Gross Income Trends • More of CYTH's Profitabilty Ratios • CYTH Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
CYTH's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
CYTH's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for CYTH's Competitors
Gross Profit Margin Profit Margin for Cyclo Therapeutics Inc 's Suppliers
Gross Profit Margin Profit Margin for CYTH's Customers

You may also want to know
CYTH's Annual Growth Rates CYTH's Profitability Ratios CYTH's Asset Turnover Ratio CYTH's Dividend Growth
CYTH's Roe CYTH's Valuation Ratios CYTH's Financial Strength Ratios CYTH's Gross Profit Growth
CYTH's Roa CYTH's Inventory Turnover Ratio CYTH's Growth Rates CYTH's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2024, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginSep 30 2024 MRQ Gross ProfitSep 30 2024 MRQ Revenue
Immunocore Holdings Plc  99.44 %$ 79.800  Millions$ 80.248  Millions
Agenus Inc  99.42 %$ 24.966  Millions$ 25.112  Millions
Lineage Cell Therapeutics Inc   98.99 %$ 3.741  Millions$ 3.779  Millions
Neurocrine Biosciences Inc   98.71 %$ 614.100  Millions$ 622.100  Millions
Vir Biotechnology Inc   97.90 %$ 2.330  Millions$ 2.380  Millions
Biocryst Pharmaceuticals Inc   97.26 %$ 113.874  Millions$ 117.085  Millions
Exelixis Inc   96.79 %$ 522.214  Millions$ 539.542  Millions
Vivosim Labs Inc   96.67 %$ 0.029  Millions$ 0.030  Millions
Tarsus Pharmaceuticals Inc   93.26 %$ 44.876  Millions$ 48.118  Millions
Cyclo Therapeutics Inc   92.81 %$ 0.217  Millions$ 0.234  Millions
Halozyme Therapeutics Inc   82.96 %$ 240.658  Millions$ 290.084  Millions
Zeo Scientifix Inc   81.91 %$ 1.019  Millions$ 1.244  Millions
Dyadic International Inc   79.78 %$ 1.562  Millions$ 1.958  Millions
Gilead Sciences Inc   79.14 %$ 5,971.000  Millions$ 7,545.000  Millions
Aim Immunotech Inc   77.14 %$ 0.027  Millions$ 0.035  Millions
Biogen Inc   74.10 %$ 1,827.100  Millions$ 2,465.800  Millions
Scilex Holding Company  73.90 %$ 10.668  Millions$ 14.436  Millions
Moderna Inc   72.40 %$ 1,348.000  Millions$ 1,862.000  Millions
Vericel Corporation  71.93 %$ 41.653  Millions$ 57.905  Millions
Coherus Oncology inc   70.69 %$ 50.033  Millions$ 70.774  Millions
Adaptive Biotechnologies Corporation  64.11 %$ 29.768  Millions$ 46.435  Millions
Bio techne Corp  63.32 %$ 183.017  Millions$ 289.017  Millions
Pluri Inc   61.35 %$ 0.200  Millions$ 0.326  Millions
Amgen Inc   61.07 %$ 5,193.000  Millions$ 8,503.000  Millions
Xtant Medical Holdings Inc   59.72 %$ 16.307  Millions$ 27.307  Millions
X4 Pharmaceuticals Inc  59.46 %$ 0.333  Millions$ 0.560  Millions
Recursion Pharmaceuticals Inc   53.69 %$ 14.003  Millions$ 26.082  Millions
Protalix Biotherapeutics inc   53.37 %$ 9.584  Millions$ 17.959  Millions
Repligen Corp  50.03 %$ 77.488  Millions$ 154.871  Millions
Adma Biologics Inc   49.86 %$ 59.659  Millions$ 119.659  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.